INVENTIVA
Biotechnology · Healthcare
Analyst
Cantor
Equibles does not estimate personal net worth.
Prakhar Agrawal is recorded as Analyst at Cantor. Prakhar Agrawal has spoken on 5 earnings calls and 1 other investor event across 6 companies, most recently for INVENTIVA on September 28, 2026. Those appearances were for INVENTIVA, Inventiva S.A. (IVA), Evommune, Inc. (EVMN), Immunovant, Inc. (IMVT), Roivant Sciences Ltd. (ROIV) and 1 other company. The companies whose calls Prakhar Agrawal spoke on are classified in the Healthcare sector.
“Firstly, can you talk about the biopsy completion rate in the trial and whether that is tracking in line with some of the recent Phase III mass trials. And a couple on weight gain.”
“Firstly, can you talk about the biopsy completion rate in the trial, and whether that is tracking in line with some of the recent Phase III mass trials? And a couple on weight gain.”
“So maybe on BREPO and NCS, just wanted to better understand the market opportunity here. You've talked about 40,000 eligible patients. would all of these be eligible for Brepo therapy and meet the inclusion exclusion criteria for the trial?”
“So maybe on BREPO and NCS, just wanted to better understand the market opportunity here. You've talked about 40,000 eligible patients. would all of these be eligible for Brepo therapy and meet the inclusion exclusion criteria for the trial?”
Cantor
Analyst
Transcript header (unverified)
INVENTIVA
Biotechnology · Healthcare
IVA
Biotechnology · Healthcare
EVMN
Biotechnology · Healthcare
IMVT
Biotechnology · Healthcare
Inventiva H1 2026 financial report
INVENTIVA